133 related articles for article (PubMed ID: 1619986)
1. Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man.
Ekstrand A; Saloranta C; Ahonen J; Grönhagen-Riska C; Groop LC
Metabolism; 1992 Jul; 41(7):692-7. PubMed ID: 1619986
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
4. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H
J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
[TBL] [Abstract][Full Text] [Related]
5. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
6. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
7. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus.
Saloranta C; Franssila-Kallunki A; Ekstrand A; Taskinen MR; Groop L
Diabetologia; 1991 Jun; 34(6):409-15. PubMed ID: 1884899
[TBL] [Abstract][Full Text] [Related]
8. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
9. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
10. Effect of steroid-therapy on insulin sensitivity in insulin-dependent diabetic patients after kidney transplantation.
Ekstrand AV
J Diabet Complications; 1991; 5(4):244-8. PubMed ID: 1779020
[TBL] [Abstract][Full Text] [Related]
11. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Piatti PM; Monti LD; Davis SN; Conti M; Brown MD; Pozza G; Alberti KG
Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
[TBL] [Abstract][Full Text] [Related]
12. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
13. Effect of decreasing plasma free fatty acids by acipimox on hepatic glucose metabolism in normal rats.
Lee KU; Park JY; Kim CH; Hong SK; Suh KI; Park KS; Park SW
Metabolism; 1996 Nov; 45(11):1408-14. PubMed ID: 8931647
[TBL] [Abstract][Full Text] [Related]
14. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K; Kashyap S; Gastaldelli A; Bajaj M; Cersosimo E
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
[TBL] [Abstract][Full Text] [Related]
15. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
16. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
Daniele G; Eldor R; Merovci A; Clarke GD; Xiong J; Tripathy D; Taranova A; Abdul-Ghani M; DeFronzo RA
Diabetes; 2014 Aug; 63(8):2812-20. PubMed ID: 24353180
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
[TBL] [Abstract][Full Text] [Related]
18. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation.
Yki-Järvinen H; Puhakainen I; Koivisto VA
J Clin Endocrinol Metab; 1991 Jun; 72(6):1268-77. PubMed ID: 2026747
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
Walker M; Agius L; Orskov H; Alberti KG
Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
[TBL] [Abstract][Full Text] [Related]
20. The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Taskinen MR
Acta Diabetol; 1994 Apr; 31(1):6-13. PubMed ID: 8043900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
